incrementalTreatment update
Emerging CAR-T and bispecific antibody approaches for WM
Waldenström's Macroglobulinemia →Summary
Bispecific antibodies (epcoritamab, CD3xCD20) and antibody-drug conjugates (loncastuximab tesirine, anti-CD19 ADC) are under early investigation in WM and related lymphomas. CAR-T therapy targeting CD19 or CD20 represents a potential curative approach but data in WM specifically remain limited to case reports and early-phase trials.
More from Waldenström's Macroglobulinemia
incrementalNew research
BTK degraders (PROTACs) enter clinical trials for B-cell malignancies
significantTreatment update
Pirtobrutinib shows activity in covalent BTK inhibitor-pretreated WM
incrementalNew research
Genomics-guided treatment selection advances in WM
significantTreatment update
Ibrutinib + venetoclax fixed-duration combination in treatment-naive WM
ID: waldenstroms-macroglobulinemia-update-5Type: treatment_updateImpact: incremental